Investigational drug · Phase 2
LXE408
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chagas Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "LXE408"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LXE408", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chagas Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "LXE408" as an intervention, largest first.
- A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).Pivotal-lookingNot yet recruiting
Drugs for Neglected DiseasesAcademic, hospital or other
NCT06997159 · 250 participants (planned) · Start Jun 15, 2026 · Primary completion Apr 5, 2028
Drug: LXE408; Miltefosine 50 MG Oral Capsule [Impavido] and 1 more · For: Localized Cutaneous Leishmaniasis
Sites: Manaus, Brazil; São Luís, Brazil; Cuiabá, Brazil · 5 sites in all
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06632600 · 130 participants (planned) · Start Apr 28, 2025 · Primary completion Jul 22, 2027
Drug: LXE408; Placebo and 1 more · For: Chagas Disease
Sites: Sylmar, California; Gainesville, Florida; Boston, Massachusetts · 22 sites in all
- A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral LeishmaniasisPivotal-lookingCompleted
Drugs for Neglected DiseasesAcademic, hospital or other
NCT05593666 · 101 participants · Start Dec 27, 2022 · Primary completion Apr 15, 2025
Drug: LXE408; AmBisome® · For: Primary Visceral Leishmaniasis
Sites: Bihār, India; Patna, India
- A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy SubjectsCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT07809919 · 88 participants · Start Dec 21, 2018 · Primary completion Sep 27, 2021
Drug: LXE408; Placebo and 1 more · For: Visceral Leishmaniasis; Chagas Disease
Sites: Overland Park, Kansas
Drugs for Neglected DiseasesAcademic, hospital or other
NCT05957978 · 52 participants · Start Mar 29, 2024 · Primary completion Jun 27, 2025
Drug: LXE408; sodium stibogluconate and 1 more · For: Primary Visceral Leishmaniasis
Sites: Gonder, Ethiopia
Newest research
PubMed records naming it or its code names, newest first.
- Redefining leishmaniasis therapy: Innovations in drug discovery and vaccine design.
Pal S, Sharma S, Sharma R · Microb Pathog 2026
- Targeting the proteasome in Leishmania donovani: developments from preclinical to Phase I and II trials.
Sundar S, Singh S, Maurya P, et al. · Expert Opin Investig Drugs 2026
- Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics.
Gupta K, Rai AK, Singh S, et al. · Inflammopharmacology 2026
- Optimization and prioritization of paediatric drugs for visceral leishmaniasis.
Masini T, Maia-Elkhoury ANS, Mondal D, et al. · Front Pediatr 2025
- The 26 S proteasome in Entamoeba histolytica: divergence of the substrate binding pockets from host proteasomes.
Joshi N, Hosen SKY, Fahad M, et al. · BMC Res Notes 2024
- Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021.
Imran M, Khan SA, Abida, et al. · Expert Opin Ther Pat 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.